A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
11
2021
revised:
17
02
2022
accepted:
19
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
The treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) remains controversial due to the limited effect of sorafenib. The aim of the study was to investigate whether apatinib could improve the efficacy of transarterial chemoembolization (TACE) for patients with HCC complicated by PVTT. The study included 109 patients with HCC and PVTT who received TACE combined with apatinib (TACE + apatinib) (53 patients) or TACE alone (56 patients) between June 2015 and January 2019. Propensity score matching (PSM) analysis was used to reduce the potential selection bias. Overall survival time (OS) and time to progression (TTP) were used to evaluate the efficacy of TACE + apatinib and TACE alone. Before PSM, TACE + apatinib significantly improved median TTP (7.0 vs. 3.0 months, The combination of TACE + apatinib might be an effective and safe treatment for HCC patients with PVTT.
Sections du résumé
Background
UNASSIGNED
The treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) remains controversial due to the limited effect of sorafenib. The aim of the study was to investigate whether apatinib could improve the efficacy of transarterial chemoembolization (TACE) for patients with HCC complicated by PVTT.
Methods
UNASSIGNED
The study included 109 patients with HCC and PVTT who received TACE combined with apatinib (TACE + apatinib) (53 patients) or TACE alone (56 patients) between June 2015 and January 2019. Propensity score matching (PSM) analysis was used to reduce the potential selection bias. Overall survival time (OS) and time to progression (TTP) were used to evaluate the efficacy of TACE + apatinib and TACE alone.
Results
UNASSIGNED
Before PSM, TACE + apatinib significantly improved median TTP (7.0 vs. 3.0 months,
Conclusion
UNASSIGNED
The combination of TACE + apatinib might be an effective and safe treatment for HCC patients with PVTT.
Identifiants
pubmed: 35356254
doi: 10.1155/2022/1255133
pmc: PMC8959956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1255133Informations de copyright
Copyright © 2022 Tao Sun et al.
Déclaration de conflit d'intérêts
All authors declare that they have no competing interests.
Références
Semin Liver Dis. 2018 Aug;38(3):242-251
pubmed: 30041276
J Clin Oncol. 2013 Sep 10;31(26):3219-25
pubmed: 23918952
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Biomed Res Int. 2019 Jul 28;2019:2141859
pubmed: 31467872
Ann Surg Oncol. 2011 Feb;18(2):413-20
pubmed: 20839057
Clin Ther. 2019 Aug;41(8):1463-1476
pubmed: 31303279
Cancer Biol Ther. 2017 Jun 3;18(6):433-438
pubmed: 28548587
Liver Cancer. 2020 Dec;9(6):682-720
pubmed: 33442540
Cancers (Basel). 2020 Apr 29;12(5):
pubmed: 32365655
World J Gastroenterol. 2006 Dec 21;12(47):7561-7
pubmed: 17171782
Oncotarget. 2017 Apr 25;8(17):29416-29427
pubmed: 28177886
Biosci Trends. 2019 Mar 14;13(1):10-22
pubmed: 30799321
Gut Liver. 2013 Nov;7(6):696-703
pubmed: 24312711
World J Gastroenterol. 2015 Mar 28;21(12):3462-71
pubmed: 25834310
J BUON. 2019 Mar-Apr;24(2):608-614
pubmed: 31128013
World J Gastroenterol. 2016 Jan 7;22(1):407-16
pubmed: 26755886
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Drugs. 2018 May;78(7):759
pubmed: 29728984
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Gut. 2001 Jan;48(1):103-9
pubmed: 11115830
PLoS One. 2014 Mar 20;9(3):e91124
pubmed: 24651044
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
ANZ J Surg. 2016 Oct;86(10):816-820
pubmed: 25088384
PLoS One. 2014 May 09;9(5):e96620
pubmed: 24817002
Ann Transl Med. 2020 Sep;8(17):1047
pubmed: 33145266
Lancet Oncol. 2018 Sep;19(9):1239-1246
pubmed: 30082170
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Exp Mol Med. 2019 Jul 8;51(7):1-11
pubmed: 31285418
Front Oncol. 2020 Jul 07;10:970
pubmed: 32733791
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Radiol. 2014 Dec;69(12):e553-61
pubmed: 25304928
Prz Gastroenterol. 2015;10(3):142-7
pubmed: 26516379
Radiology. 2014 Jul;272(1):284-93
pubmed: 24708192
World J Gastroenterol. 2016 Aug 28;22(32):7289-300
pubmed: 27621575
BMC Gastroenterol. 2020 Jun 29;20(1):205
pubmed: 32600349